Vestcor Inc acquired a new position in shares of C4 Therapeutics, Inc. (NASDAQ:CCCC – Free Report) during the 3rd quarter, HoldingsChannel.com reports. The firm acquired 29,500 shares of the company’s stock, valued at approximately $168,000.
A number of other hedge funds have also recently bought and sold shares of the company. Lynx1 Capital Management LP raised its position in shares of C4 Therapeutics by 89.3% during the second quarter. Lynx1 Capital Management LP now owns 6,880,527 shares of the company’s stock worth $31,788,000 after acquiring an additional 3,245,865 shares during the last quarter. Wasatch Advisors LP raised its holdings in C4 Therapeutics by 17.1% during the 3rd quarter. Wasatch Advisors LP now owns 5,677,368 shares of the company’s stock worth $32,361,000 after purchasing an additional 830,218 shares during the last quarter. ArrowMark Colorado Holdings LLC lifted its position in C4 Therapeutics by 6.0% during the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 1,319,484 shares of the company’s stock valued at $7,521,000 after purchasing an additional 75,126 shares during the period. Point72 Asset Management L.P. boosted its stake in shares of C4 Therapeutics by 331.4% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,201,848 shares of the company’s stock valued at $6,851,000 after purchasing an additional 923,268 shares during the last quarter. Finally, Wellington Management Group LLP grew its position in shares of C4 Therapeutics by 24.7% during the 3rd quarter. Wellington Management Group LLP now owns 286,041 shares of the company’s stock worth $1,630,000 after buying an additional 56,696 shares during the period. 78.81% of the stock is currently owned by institutional investors.
C4 Therapeutics Price Performance
Shares of CCCC stock opened at $4.38 on Friday. The stock has a market cap of $309.18 million, a PE ratio of -2.58 and a beta of 2.92. The stock has a 50-day moving average of $5.17 and a 200-day moving average of $5.47. C4 Therapeutics, Inc. has a one year low of $3.77 and a one year high of $11.88.
Analyst Upgrades and Downgrades
Separately, Stephens started coverage on shares of C4 Therapeutics in a report on Monday, November 18th. They issued an “equal weight” rating and a $4.00 price objective on the stock. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, C4 Therapeutics has a consensus rating of “Hold” and a consensus target price of $10.00.
Read Our Latest Report on CCCC
C4 Therapeutics Company Profile
C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.
Further Reading
- Five stocks we like better than C4 Therapeutics
- Health Care Stocks Explained: Why You Might Want to Invest
- FinWise Bancorp’s CEO Talks Strategy Behind Fintech Success
- How to Evaluate a Stock Before Buying
- Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
- How to Use High Beta Stocks to Maximize Your Investing Profits
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
Want to see what other hedge funds are holding CCCC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C4 Therapeutics, Inc. (NASDAQ:CCCC – Free Report).
Receive News & Ratings for C4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.